MONTREAL, QUEBEC--(Marketwire - July 24, 2009) - Ambrilia Biopharma Inc. (TSX:AMB) announced today that its Board of Directors has approved the termination of the phase III clinical Study 303 as part ...

As of November 26 at 8:15:07 AM GMT+1. Market Open.

MONTREAL, QUEBEC--(MARKET WIRE)--May 14, 2008 -- Ambrilia Biopharma Inc. (Toronto:AMB.TO - News) today reported positive 24-week Phase III ("Study 301") top-line results for its proprietary ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

PHILADELPHIA, April 17, 2025 /PRNewswire/ -- The City of Philadelphia, Philadelphia Works, and the School District of Philadelphia announce the upcoming application period for Career Connected ...